Mitochondrial metabolism as a potential novel therapeutic target for lung adenocarcinoma
Makoto Fujiwara(Hiroshima University), Morihito Okada(Hiroshima University)
Cited by 0
Related Papers
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial
|The Lancet|2022|1.6k
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|The Lancet Oncology|2019|636
Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial
|Journal of Thoracic and Cardiovascular Surgery|2019|496